Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07201519 · ClinicalTrials.gov registry record · Phase 2
Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
A Phase 2 study of Colorectal Cancer Metastatic and Intrahepatic Cholangiocarcinoma, sponsored by Michael J Cavnar, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT07201519: Recruiting Phase 2 study of Colorectal Cancer Metastatic and Intrahepatic Cholangiocarcinoma, sponsored by Michael J Cavnar, MD.
NCT07201519 is a Phase 2 study of Colorectal Cancer Metastatic and Intrahepatic Cholangiocarcinoma that is actively recruiting participants, run by Michael J Cavnar, MD. The registered enrollment target is 80 participants, below the 201-participant average among 18 other Colorectal Cancer Metastatic trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07201519, a Phase 2 study of Colorectal Cancer Metastatic and Intrahepatic Cholangiocarcinoma, is actively recruiting participants, sponsored by Michael J Cavnar, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to help learn about the safety and feasibility of hepatic artery infusion chemotherapy for those who have colorectal liver metastases, both resectable and unresectable, or unresectable intrahepatic cholangiocarcinoma. The main questions it aims to answer are: * safety and feasibility of installing a pump that deliveries chemotherapy to the hepatic artery (the blood vessel that supplies blood to the liver) * help learn more about the safety of patients having pump refills at home or a local clinic versus having it routinely done at the hospital Participants will have surgery to install a pump which is a standard surgical procedure. After surgery, participants will select to either receive treatment at the hospital facility or with a community oncologist that will provide cancer care to participants close to home, rather than in a large hospital or academic medical center. The main treatment on study will last about 3-4 months.
Primary Outcome
The primary outcome is safety, defined as: continued functional / in-use HAI pump (either for FUDR fills or maintenance saline/glycerine fills) at 3-months.
Conditions Studied
Interventions
- DEVICE Hepatic Artery Infusion Pump (HAIP)
- PROCEDURE Standard Treatment
- PROCEDURE Community Treatment
- DRUG Systemic Chemotherapy Standard of Care
- DRUG Standard Of Care targeting driver mutations
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-01-23 |
| Est. Completion | 2030-02 |
| Phase | Phase 2 |
What NCT07201519 shows while recruiting
NCT07201519 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 201-participant average among 18 other Colorectal Cancer Metastatic trials with a reported enrollment target (60% lower).
The record links to 2 conditions, with Colorectal Cancer Metastatic appearing as the primary indexed condition, and to 5 interventions - of which Hepatic Artery Infusion Pump (HAIP) is the first listed.
NCT07201519 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT07201519 about?
NCT07201519 is a clinical study titled "Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy". The goal of this clinical trial is to help learn about the safety and feasibility of hepatic artery infusion chemotherapy for those who have colorectal liver metastases, both resectable and unresectable, or unresectable intrahepatic cholangiocarcinoma. The main questions it aims to answer are: * sa...
What is the current status of trial NCT07201519?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2026-01-23. Estimated completion is 2030-02.
What conditions does trial NCT07201519 study?
This clinical trial studies the following conditions: Colorectal Cancer Metastatic, Intrahepatic Cholangiocarcinoma.
What interventions are being tested in trial NCT07201519?
The interventions under investigation include: Hepatic Artery Infusion Pump (HAIP) (DEVICE), Standard Treatment (PROCEDURE), Community Treatment (PROCEDURE), Systemic Chemotherapy Standard of Care (DRUG), Standard Of Care targeting driver mutations (DRUG).
Who is sponsoring clinical trial NCT07201519?
This trial is sponsored by Michael J Cavnar, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07201519 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07201519's enrollment target sits among peer trials
80 4th of 18 higher than 14 of 18 other Colorectal Cancer Metastatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer Metastatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
RECRUITING · Phase 2
-
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
RECRUITING · Phase 2
-
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
RECRUITING · Phase 2
-
Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
ACTIVE NOT RECRUITING · Phase 2
-
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
COMPLETED · Phase 2
-
A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI